Skip to main content
SpringerLink
Log in

Vitamin D analogues — new therapeutic agents for secondary hyperparathyroidism

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Brown AJ, Coyne DW. Vitamin D analogs: new therapeutic agents for secondary hyperthyroidism Treat Endocrinol 2002; 1(5): 313–27

    Article  PubMed  CAS  Google Scholar 

  2. Hamdy NA, Kanis JA, Beneton MN, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310: 358–63

    Article  PubMed  CAS  Google Scholar 

  3. Malluche HH, Ritz E, Lange HP, et al. Bone histology in incipient and advanced renal failure. Kidney Int 1976; 9: 355–62

    Article  PubMed  CAS  Google Scholar 

  4. Coburn JW, Elangovan L. Prevention of metabolic bone disease in the pre-end-stage renal disease setting. J Am Soc Nephrol 1998; 9: S71–7

    PubMed  CAS  Google Scholar 

  5. Chertow GM, Dillon MA, Amin N, et al. Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial. J Ren Nutr 2000; 10: 125–32

    Article  PubMed  CAS  Google Scholar 

  6. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in haemodialysis patients. Kidney Int 2002; 62: 245–52

    Article  PubMed  CAS  Google Scholar 

  7. Ritz E, Kuster S, Schmidt-Gayk H, et al. Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). Nephrol Dial Transplant 1995; 10: 2228–34

    PubMed  CAS  Google Scholar 

  8. Przedlacki J, Manilius J, Huttunen K. Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure. Nephron 1995; 69: 443–7

    Article  Google Scholar 

  9. Tsukamoto Y, Hanaoka M, Matsuo T, et al. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis 2000; 35: 458–64

    Article  PubMed  CAS  Google Scholar 

  10. Martin KJ, Gonzalez EA, Gellens ME, et al. Therapy of secondary hyperparathyroidism with 19-nor-1′,25-dihydroxyvitamin D2. Am J Kidney Dis 1998; 32: S61–6

    Article  PubMed  CAS  Google Scholar 

  11. Llach F, Yudd M. Paricalcitol in patients with calcitriol-resistent secondary hyperparathyroidism. Am J Kidney Dis 2001; 38 Suppl. 5: 34–40

    Google Scholar 

  12. Coyne DW, Grieff M, Ahya SN, et al. Differential effects of acute administration of 19-nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on serum calcium and phosphorus in haemodialysis patients. Am J Kidney Dis. 2002 Dec; 40(6): 1283–8.

    Article  PubMed  CAS  Google Scholar 

  13. Tan Jr AU, Levine BS, Mazess RB, et al. Effective suppression of parathyroid hormone by 1′-hydroxy-vitamin D2 in haemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997; 51: 317–23

    Article  PubMed  CAS  Google Scholar 

  14. Frazao JM, Chesney RW, Coburn JW. Intermittent oral 1′hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. Nephrol Dial Transplant 1998; 3: 68–72

    Article  Google Scholar 

  15. Maung HM, Elangovan L, Frazao JM, et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001; 37: 532–43

    Article  PubMed  CAS  Google Scholar 

  16. Nishizawa Y, Morii H, Ogura Y, et al. Clinical trial of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 in uremic patients on haemodialysis: preliminary report. Contrib Nephrol 1991; 90: 196–203

    PubMed  CAS  Google Scholar 

  17. Akiba T, Marumo F, Owada A, et al. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in haemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1998; 32: 238–46

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vitamin D analogues — new therapeutic agents for secondary hyperparathyroidism. Drugs Ther. Perspect 19, 14–16 (2003). https://doi.org/10.2165/00042310-200319060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319060-00005

Keywords

Search

Navigation